08045800513
Send Inquiry
Send InquiryMetformin-500 mg, Glibenclamide 5 mg & Pioglitazone 15 mg
MOQ : 15-30 Boxes
Metformin-500 mg, Glibenclamide 5 mg & Pioglitazone 15 mg Specification
- Drug Type
- Specific Drug
- Ingredients
- Glimepride 2 mg + Pioglitazone 30 mg (SR)
- Physical Form
- Tablets
- Function
- Other
- Recommended For
- 3rd line treatment for Type 2 Diabetes Mellitus, when all other treatment fails
Metformin-500 mg, Glibenclamide 5 mg & Pioglitazone 15 mg Trade Information
- Minimum Order Quantity
- 15-30 Boxes
- Payment Terms
- Western Union, Paypal, Cash Advance (CA), Cash in Advance (CID), Cheque
- Sample Policy
- Sample costs shipping and taxes has to be paid by the buyer
- Packaging Details
- Blister Pack, 2*5*10
- Main Domestic Market
- All India
- Certifications
- WHO-GMP
Metformin-500 mg, Glibenclamide 5 mg & Pioglitazone 15 mg About
Metformin-500 mg, Glibenclamide 5 mg, and Pioglitazone 15 mg tablets are designed for the targeted management of Type 2 Diabetes Mellitus, particularly as a third-line treatment option when standard therapeutic approaches fail. Formulated with a precise combination of active ingredients, these tablets ensure effective glycemic control by addressing multiple mechanisms of action. Metformin reduces glucose production in the liver, Glibenclamide stimulates pancreatic insulin secretion, and Pioglitazone enhances insulin sensitivity in peripheral tissues. Suitable for adults and aged individuals, this specific drug is an optimal solution for healthcare providers handling challenging diabetic cases. Manufactured in tablet form, they offer convenience and reliability for patients requiring advanced diabetes management strategies.
FAQs of Metformin-500 mg, Glibenclamide 5 mg & Pioglitazone 15 mg:
Q: What is the recommended use for this product?
A: This tablet is recommended as a third-line treatment for Type 2 Diabetes Mellitus when all other treatment options fail.Q: Who is this product suitable for?
A: It is suitable for adults and aged individuals requiring advanced diabetes management.Q: How does this product work?
A: Metformin reduces liver glucose production, Glibenclamide stimulates insulin secretion, and Pioglitazone enhances insulin sensitivity.Q: What is the physical form of this product?
A: This product is available in tablet form for convenience and efficacy.Q: What type of drug is this?
A: This is a specific drug formulated for targeted treatment of Type 2 Diabetes Mellitus.
Tell us about your requirement
Price:
Quantity
Select Unit
- 50
- 100
- 200
- 250
- 500
- 1000+
Additional detail
Mobile number
Email
More Products in Diabetic Tablets Category
Metformin,Glimperide & Atorvastatin Combination
Minimum Order Quantity : 1530 Boxes
Drug Type : Specific Drug
Function : Other
Physical Form : Tablets
Ingredients : Glimepride 2 mg + Pioglitazone 30 mg (SR)
Recommended For : Treatment of Type 2 Diabetes Mellitus associated with dyslipidemia
Voglibose 0.2 mg & 0.3 mg
Minimum Order Quantity : 1530 Boxes
Drug Type : Specific Drug
Function : Other
Physical Form : Tablets
Ingredients : Glimepride 2 mg + Pioglitazone 30 mg (SR)
Recommended For : To enhance Glycaemic Control
Metformin 500 mg & Gliclazide 80 mg (Sustained Release)
Minimum Order Quantity : 1530 Boxes
Drug Type : Specific Drug
Function : Other
Physical Form : Tablets
Ingredients : Glimepride 2 mg + Pioglitazone 30 mg (SR)
Recommended For : Type 2 Diabetes Mellitus
Tenegliptin with Metformin Combination
Minimum Order Quantity : 1530 Boxes
Drug Type : Specific Drug
Function : Other
Physical Form : Tablets
Ingredients : Glimepride 2 mg + Pioglitazone 30 mg (SR)
Recommended For : Type 2 Diabetes Mellitus
We deal only in bulk orders.
Contact Details
- Plot No. 364, Industrial Area, Phase-1,Chandigarh - 160002, India
- Phone : 08045800513
GST : 04AAHCS5485R1ZJ
- Mr Sanjeev Kumar Sethi (Managing Director)
- Mobile : 08045800513
- cmd@solitairegroup.in
- Mobile :+919815777744
SOLITAIRE PHARMACIA PVT. LTD.
All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Private Limited.
Developed and Managed by Infocom Network Private Limited.
